

Synthesis, characterization and biological activities of some new acid hydrazones derived from ethyl-2-(2, 5-dichloroanilido) acetohydrazide

RAJ N. SHARMA, K.P. SHARMA, S.N. DIXIT and R.L. TAIGAR

Chemical Laboratories, Government SMS Science College, Gwalior - 474 002 (India).

(Received: December 22, 2009; Accepted: February 06, 2010)

ABSTRACT

A series of new acid hydrazones have been synthesized by the reaction of ethyl-2-(2, 5-dichloroanilido) acetohydrazide with various carbonyl compounds in 27 to 92 % yield. Hydrazones are white, brown and yellow colour solids, having high melting points. Newly synthesized compounds (1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16 and 17) have been tested for their *antibacterial activity* against gram positive bacteria *S.albus*, *S.aureus* and gram negative bacteria *E.coli* and *Pseudomonas piosineus*. The compound 2, 3, 5, 12, 13, 14, and 15 shown significant activity and compound 1, 4, 6, 7, 8, 9, 16 and 17 have shown moderate activity. The same compounds were tested for their *antifungal activity* against *Candida albicans*, *Aspergillus niger* and *Alternaria alternata* at concentration of 30 mg/mL using savored dextrose agar media. The compound 2, 5, 12, 13, 14, and 15 shown significant activities and compound 1, 4, 8, 9, 16 and 17 have shown moderate activity against *Candida albicans* and *Aspergillus niger*. All the other compounds did not show significant activity against the fungi at the concentration used. Some new compounds have been tested for *anti tubercular activity* in-vitro using *Mycobacterium tuberculosis*. The compounds were incorporated into Lowenstein Jensen egg medium having concentrations of 10 and 100 mg/mL and were inoculated with *Mycobacterium tuberculosis*, H₂₇, Rv strains, incubated at 37°C and observed, the compound *Ethyl-2-(2,5-dichloroanilido) acetohydrazide*, *Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 4-N,N-Bis -2'- cyanoethylamino benzaldehyde*, *Ethyl-2-(2,5-dichloroanilido) acetohydrazone of 2-methyl-4-N,N-Bis-2'- cyanoethylaminobenzaldehyde* and *Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 5-Chloro Salicylaldehyde* inhibited the growth of *Mycobacterium tuberculosis* at 100mg/mL concentration other compounds were found to be inactive.

Key words: Malonester, acidhydrazide, acidhydrazones, synthesis, characterization and biological activities.

INTRODUCTION

Hydrazones possessing an azometine - NHN=CH- Proton constitute an important class of compounds for new drug development. Therefore, many researchers have synthesized these compounds as target structures and evaluated their biological activities. Acidhydrazides have frequently been investigated for testing their potentiality as

tuberculostats¹⁻⁸. Hydrazides and their condensation products have displayed diverse range of biological properties such as bacteriocidal⁹⁻¹⁰, anti-fungal¹¹, anti-convulsant¹²⁻¹⁵, anti-helminthic¹⁶, anti-tumor¹⁷⁻²⁰, anti-leprotic²¹, anti-malarial²²⁻²³, anti-cancer²⁴⁻³¹, anti-depressant³², anti-HIV³³, analgesic-anti-inflammatory³⁴, leishmanicidal³⁵, vasodilator activities³⁶.

EXPERIMENTAL

All chemicals used were of A.R. grade (either of B.D.H. or Excel-R or Extra pure E. Merk quality). The structures of the compounds were determined by elemental analysis, IR and NMR spectral data. IR spectra (KBr) are recorded on a perkin-Elmer 283 spectrophotometer. NMR spectra (CDCl_3) are recorded on Varian EM 360 L spectrophotometer. Melting points of the compounds are determined in open capillary tubes and are uncorrected. Purity of the compounds is checked on T.L.C. using Silica Gel-G. Elemental analysis is performed on Carlo-Erba 1108 analyzer.

Synthesis of Ethyl-2-(2, 5- dichloroanilido) Ethanoate [1]

A mixture of 2, 5-dichloroaniline (10ml) and diethylmalonate (20ml) was refluxed for forty five minutes in a round bottomed flask fitted with an air condenser of such a length (14") that ethanol formed escaped and diethylmalonate flowed back into the flask. Contents were cooled, ethanol (30 ml) was added, when malon-2, 5dichlorodianilide separated out. It was filtered under suction. The filtrate was poured on to crushed ice (Ca160g) and stirred when ethyl-2-(2, 5-dichloroanilido) ethanoate precipitated as green mass. On recrystallization from aqueous ethanol (50%), ester was obtained as white crystals. Yield: 72%, M. P.: 87°C, M. W.: 276. Analytical calculation for $C_{11}H_{11}N_1O_3Cl_2$: Found: C 39.22, H: 03.20, O: 14.23, N: 4.13, Cl: 21.12, Calculated. C: 39.21, H: 03.26, O: 14.26, N: 04.15, Cl: 21.16. *IR [KBr] V_{max} Cm⁻¹*: 1670-1665 [C=O diketone], 1290 [-C-O- Ester], 780-775 [2,5- disubstituted benzene], 1590, 1520 ,1440 [C=C Ring stretching], 3155 [N-H Stretching], 3040[C-H aromatic], 1330-1322 [C-H Stretching].

NMR Spectra (δ Me_2CO), 1.2-1.3 (3H, t, CH_3), 2.23 (2H, s, CH_2), 4.1-4.24 (2H, q, CH_2), 7.1-7.26 (4H, m, ArH).

Synthesis of Ethyl-2-(2, 5- dichloroanilido) acetohydrazide [2]

Ethyl-2-(2, 5-dichloroanilido) ethanoate (9.54 gm; 0.03 mol), ethanol (10 ml) and hydrazine hydrate (15 ml; 80%) were mixed together and stirred for thirty five minutes. Ethyl-2-(2, 5-dichloroanilido) acetohydrazide was filtered under

suction and recrystallised from ethanol in white crystals. Yield: 80%, MP = 168°C, MW 262:

Analytical calculation for $C_9H_9N_3O_2Cl_2$

Calculated ; N 09.04 ,C 41.32 ,H 03.01 ,O 10.33, Cl 15.28, Found; N 09.01, C 41.30, H 03.00, O 10.31, Cl 15.27 .

IR [KBr] V_{max} cm⁻¹

3160 [N-H Stretching], 3048 [C-H aromatic], 1670 [C=O diketone], 1432 [C-Cl aromatic], 1595, 1520, 1445 [C=C ring stretching]. NMR Spectra (δ DMSO): 2.44 (2H, s, CH_2), 3.2 (3H, s, CH_3), 4.22-4.32 (1H, t, N-H), 7.2-7.6 (3H, m, ArH).

Synthesis of Ethyl-2-(2, 5-dichloroanilido) acetohydrazone [3]

Ethyl-2-(2, 5-dichloroanilido) acetohydrazide (0.001 mol) and (0.001 mol) of aromatic aldehyde or ketone [such as benzaldehyde] dissolve in absolute alcohol and added 2-drops of conc. H_2SO_4 and stirred for 25 minutes. It was filtered under suction and recrystallised from hot ethanol. *M.F. C₁₆H₁₃O₂N₃Cl₂*, Colour: Silver white, Yield: 91%, M.P= 214 °C, F.W: 350,

Analytical calculation for $C_{16}H_{13}O_2N_3Cl_2$, Calculated

N 12.04, C 54.85, H 03.71, O 09.14, Cl 20.28, Found: N 11.98, C 54.82, H 03.70, O 10.31, Cl 20.26.

IR Absorption band (cm⁻¹)

3150 (N-H stretching), 2960–2970 (C–H aliphatic), 1662–1660 (C=O Ketone), 790–780 (C–Cl Stretching), 760–765 (2, 5-disubstituted benzene).

NMR Spectra

(δ DMSO), 2.20(2H, s, CH_2), 4.22(1H, s, NH), 6.96–7.1 (10 H, m, ArH). Synthetic strategy has been outlined in scheme-I. Mechanism for the formation of acid hydrazones is given in chart-I.

Biological evaluation

Anti-bacterial activity

Newly synthesized compounds (1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16 and 17) have been tested for their antibacterial activity against gram positive bacteria *S. albus*, *S. aureus* and gram negative bacteria *E.coli* and *P. piosineus* by agar

Table 1: Physical and analytical data of new compounds: Acid hydrazones derived from 2-(2,3-dichloroanilido) acetohydrazide

No.	S. Aldehyde / Ketone	R ₁	R ₂	MP (°C)	Yield (%)	Formula Weight	Molecular formula	Colour	Elemental analysis			
									C	H	O	N
1.	Benzaldehyde	H	Ph	214	90	350	C ₁₆ H ₁₃ O ₂ N ₃ Cl ₂	White	54.84 (54.82)	3.70 (3.68)	9.15 (9.12)	12.04 (11.97)
2.	Vanilline	H	Ph_{OMe}(3) _{OH}(4)	208	83	396	C ₁₇ H ₁₅ O ₄ N ₃ Cl ₂	White	51.51 (51.50)	3.77 (3.74)	16.16 (16.16)	10.62 (10.55)
3.	5-Chloro salicylaldehyde	H	Ph_{OH}(2) _{Cl}(5)	225	87	399.5	C ₁₆ H ₁₁ O ₃ N ₃ Cl ₃	White	48.05 (48.02)	2.72 (2.70)	12.03 (12.01)	10.56 (10.52)
4.	5-Bromo salicylaldehyde	H	Ph_{OH}(2) _{Br}(5)	217	92	492	C ₁₆ H ₁₂ O ₃ N ₃ Cl ₂ Br	Silver	39.04 (39.03)	2.48 (2.45)	9.74 (9.71)	8.55 (8.53)
5.	2-Nitro vanilline	H	Ph_{NO} ₂ (2) _{OCH} ₃ (3) _{OH}(4)	226	74	441	C ₁₇ H ₁₄ O ₆ N ₄ Cl ₂	Cream	45.24 (45.22)	3.18 (3.15)	21.77 (21.75)	12.71 (12.69)
6.	O-Nitro benzaldehyde	H	Ph - NO ₂ (2)	228	89	395	C ₁₆ H ₁₂ O ₄ N ₄ Cl ₂	White	48.64 (48.59)	3.03 (3.01)	16.24 (16.21)	14.16 (14.15)
7.	2-Nitro	H	Ph_{NO} ₂ (2) _{OMe}(3) _{OH}(4) _{Br}(5)	219	58	567	C ₁₇ H ₁₃ O ₆ N ₄ Cl ₂ Br	Cream	35.97 (35.95)	2.29 (2.27)	16.93 (16.91)	9.87 (9.85)

Table 2: Tuberculostatic Activity of new acid hydrazones

S. No.	Compounds	Growth at conc. [mg/mL]	
		10	100
1.	<i>Ethyl-2-(2,5-dichloroanilido) acetohydrazide</i>	+	0
2.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 3 -Nitro 6-hydroxy acetophenone	+	+
3.	<i>Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 4 -N,N-Bis 2'- cyanoethylamino benzaldehyde</i>	+	0
4.	<i>Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 2 -methyl -4-N,N-Bis 2'- cyanoethylamino benzaldehyde</i>	+	0
5.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 2 -methoxy -4-N,N-Bis 2'- cyanoethylamino benzaldehyde	+	+
6.	<i>Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of acetophenone</i>	+	+
7.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of salicylaldehyde	+	+
8.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of anisicaldehyde	+	+
9.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 2-Nitro vanilline	+	+
10.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 2 -chloro benzaldehyde	+	+
11.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of benzaldehyde	+	+
12.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of b -Ionone	+	+
13.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of Vanilline	+	+
14.	<i>Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 5 -Chloro Salicylaldehyde</i>	+	0
15.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 5 -bromo Salicylaldehyde	+	+
16.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of o -Nitro benzaldehyde	+	+
17.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 2 -Nitro 5-bromo vanilline	+	+
18.	Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 3,5 -dichloro-2-hydroxy benzaldehyde	+	+

'+'and '0' indicate presence and inhibition of growth respectively.

The compound Ethyl-2-(2,5-dichloroanilido) acetohydrazide, Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 4-N,N-Bis -2'- cyanoethylamino benzaldehyde, Ethyl-2-(2,5-dichloroanilido) acetohydrazone of 2-methyl-4-N,N-Bis-2'-cyanoethylaminobenzaldehyde and Ethyl-2-(2, 5-dichloroanilido) acetohydrazone of 5-Chloro Salicylaldehyde inhibited the growth of *Mycobacterium tuberculosis* at 100mg/mL concentration other compounds were found to be inactive. Results are assembled in Table 2.

RESULTS AND DISCUSSION

New acid hydrazones have been synthesized by the reaction of Ethyl-2-(2, 5-dichloroanilido) acetohydrazide with various Carbonyl Compounds in 27 to 92% yield. Hydrazones are white, brown and yellow colour solids, having high melting points. The structure of all the compounds are confirmed by IR, PMR, and Mass spectral data and are further supported by correct elemental analysis. Newly synthesized compounds (1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16 and 17) have been tested for their antibacterial activity against ⁹H positive bacteria *S. albus*, *S. aureus* and ⁹H negative bacteria *E. coli* and *Pseudomonas pidsineus*. The compound 2, 3, 5, 12, 13, 14 and 15 shown significant activities and compound 1, 4, 6, 7, 8, 9, 16 and 17 have shown moderate activity. The same compounds were tested for their antifungal activity against *Candida albicans*, *Aspergillus niger* and *Alternaria alternata* at concentration of 30 mg/mL using Savored dextrose agar media. The compound 2, 5, 12, 13, 14 and 15 shown significant activity and compound 1, 4, 8, 9, 16 and 17 have shown moderate activity against *Candida albicans* and *Aspergillus niger*. All the other compounds did not show significant activity against the fungi at the concentration used.

Chart 1: Mechanism of formation of new acid hydrazones]

plate disc diffusion method at 30 µg/mL concentration. Ampicillin and Tetracycline were used as a reference compounds. The compound 2, 3, 5, 12, 13, 14 and 15 shown significant activities and compound 1, 4, 6, 7, 8, 9, 16 and 17 have shown moderate activity.

Anti-fungal activity

The same compounds were tested for their antifungal activity against *Candida albicans*, *Aspergillus niger* and *Alternaria alternata* at concentration of 30 mg/mL using Savored dextrose agar media. The compound 2, 5, 12, 13, 14 and 15 shown significant activity and compound 1, 4, 8, 9, 16 and 17 have shown moderate activity against *Candida albicans* and *Aspergillus niger*. All the other compounds did not show significant activity against the fungi at the concentration used.

Tuberculostatic Activity

Some new compounds have been tested for anti-tubercular activity in-vitro using *Mycobacterium tuberculosis*. The compounds were incorporated into Lowenstein Jensen egg medium having concentrations of 10 and 100 mg/mL and were inoculated with *Mycobacterium tuberculosis*, H₂₇, Rv strains, incubated at 37°C and observed weekly for the growth of organism for eight weeks.

negative bacteria *E.Coli* and *Pseudomonas piosineus* by agar plate disc diffusion method at 30 µg/mL concentration. Ampicillin and Tetracycline were used as a reference compounds. The compound 2, 3, 5, 12, 13, 14 and 15 shown significant activities and compound 1, 4, 6, 7, 8, 9, 16 and 17 have shown moderate activity. The same compounds were tested for their antifungal activity against *Candida albicans*, *Aspergillus niger* and *Alternaria alternata* at concentration of 30 mg/mL using Savored dextrose agar media. The compound 2, 5, 12, 13, 14 and 15 shown significant activities and compound 1, 4, 8, 9, 16 and 17 have shown moderate activity against *Candida albicans* and *Aspergillus niger*. All the other compounds did not show significant activity against the fungi at the concentration used. The same compounds were tested for their antitubercular activity against *Mycobacterium tuberculosis*. The compound Ethyl-2-(2,5-dichloroanilido) acetohydrazide, Ethyl-2-(2,5-dichloroanilido) acetohydrazone of 4-N,N-Bis-2'-cyanoethylamino benzaldehyde, Ethyl-2-(2,5-dichloroanilido) acetohydrazone of 2-methyl-4-N,N-Bis-2'-cyanoethylaminobenzaldehyde and Ethyl-2-(2,5-dichloroanilido) acetohydrazone of 5-Chloro Salicylaldehyde inhibited the growth of *Mycobacterium tuberculosis* at 100mg/mL concentration other compounds were found to be inactive.

Fig. 1.

Mycobacterium tuberculosis at 100mg/mL concentration other compounds were found to be inactive.

CONCLUSION


Newly synthesized compounds (1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16 and 17) have been tested for their antibacterial activity against gram positive bacteria *S. albus*, *S. aureus* and gram

ACKNOWLEDGEMENTS

The authors are thankful to Director, C. D. R. I. Lucknow (Uttar Pradesh), for elemental analysis, Director, Tuberculosis Research Centre, Amargadh (Gujrat), for testing tuberculostatic activity and Director, D. R. D. E. Gwalior (Madhya Pradesh), for spectral studies, and Director, Cancer Hospital and Research Institute, Gwalior (Madhya Pradesh), for Biological activities. We are also grateful to principal SMS Government Model Science College, Gwalior (Madhya Pradesh), for providing research facilities.

REFERENCES

1. Buu-Hoi, Rene Royer, J. J. Jouin, J. Lecocq and D. Guettier, *Bull. Soc. Chim., France*, 128-36 (1947).
2. Shichiro, Kakimoto and Kenichi Yamamoto, *J. Pharm. Soc. Japan*, **74**: 997-9 (1954), C. A. **49**: 11650 g (1955).



3. L. Stoicescu – Crivetz and L. Mandasescu, Acad. rep. populare Romine, *Studii, Cercetare, Chim.* 4: 175-82 (1956), C.A. Vol. 51,10421 h (1957).
4. Agarwal S. K., Chandra R., Gupta R., Tutlani D.R., *J. Inst. Chem. (India)*, **59**(5) 225 (1987), C.A. **108**: 164594 w (1988).
5. Swiss **419**: 139 (1967), C.A. **68**: 29709 C (1968).
6. R. Cavier and R. Rips (Fac. Pharm, Paris), *J. Med. Chem* **8**(5): 706-8 (1965).
7. Martynovskii A. A., Samura B.A. and Co-workers, Med. Inst. Zaporzne, USSR, Khim. Farm. Zh. **24**(7): 31-2 (1990), C.A. **113**: 164948 t (1990).
8. Strokin, Yu. V, Karasovskii, I.A. and co-workers, (Bashk. Med.Inst., UFA, USSR), Khim.Farm.Zh,24 (7) 45-8 (1990), C.A. **114**: 172 e, (1991).
9. Gardner, T.S., Wenis, E., and Lee, J., *J. Org. Chem.*, **26**: 1514 (1961).
10. Willy, R.H., Slaymaker, S., and Krans H., *J. Org. Chem.* **22**: 204 (1957).
11. Omar, A., Mohsen, M.E., Farghaly, A.M., Hazzai, A.A.B., Eshba, N.H. (Fac. Pharm. Univ. Alexandria, Egypt). *Pharmazie* (1980), C.A., **95**: 25382 a (1981).
12. Bhat, A.K., Bhamaria, R.P., Patel, M.R., Bellare, R.A., and Deliwalia, C.V., *Indian J. Chem.* **10**: 694 (1972).
13. Rollas, S., Kucukguzel, S. G., *Molecules* **12**: 1910-1939 (2007).
14. Rollas S., Gulerman, N., Erdeniz, H, *Farmaco* **57**: 17 (2002).
15. Kaymakcioglu K.B., Oruc, E.E., Unsalan, S., Kandemirli,F., Shvets, N., Rollas, S., Anatholy, D., *Eur. J. Med. Chem.* **41**: 1253-1261 (2006).
16. Kalsi, R., Shrimali, M., Bhalla, T.N., Barthwal, J. P., *Indian J. Pharm. Sci.* **41**: 353-359 (2006).
17. Ragavendran, J., Sriram,D., Patel,S., Reddy,I., Bharathwajan,N., Stables, J., yogeewari, P., *Eur. J. Med. Chem.* **42**: 146-151 (2007).
18. Salgin-Goksen, U., Gokhan-Kelekci, N., Goktas, O., Koysal, Y., Kilic, E., Isik, S., Aktay,G., Ozalp, M., *Bioorg. Med. Chem.* **15**: 5738- 5751 (2007).
19. Kucukguzel, S.G., Mazi, A. , Sahin, F., Ozturk S., Stables, J.P., *Eur. J. Med. Chem.* **38**: 1005-1009 (2003).
20. Loncle, C., Runnel, J., Vidal, N., Dherbomez, M., Letourneau, Y., *Eur. J. Med. Chem.* **39**: 1067-1071 (2004).
21. Masunari, A., Tavares, L.C., *Bioorg. Med. Chem.* **15**: 4229-4236 (2007).
22. Sriram, D., Yogeewari, P., Madhu, K., *Bioorg. Med. Chem. Lett.* **15**: 4502- 4505 (2005).
23. Bijev, A., *Lett.Drug Des. Discov.*, **03**: 506-512 (2006).
24. Nayyar, A., Jain, R., *Med. Chem.* **12**: 1873-1886 (2005).
25. Scior, T., Garces-Eisele, S.J., *Curr.Med. Chem.* **13**: 2205-2219,(2006).
26. Janin, Y., *Bioorg. Med.Chem.* **15**: 2479-2513 (2007).
27. Ulusoy, N., Gursoy, A., Otuk, G., Kiraz, M. *Farmaco* **56**: 947-952 (2001).
28. Linhong j, Jiang C, Baoan S, Zhuo C, Song Y, Qianzhu L, Deyu H and Ruiqing X, *Bioorg Med Chem Lett.*, **16**: 5036-5040 (2006).
29. Caleta I, Grdisa M, Mrvos DS, Cetina M, Tralic KV, Pavelic K and Karminska G *IL Farmaco*, **59**: 297-305 (2004).
30. Geoffrey W, Tracey DB, Patrizia D, Angela S, Dong FS, Andrew DW and Malcolm FGS, *Bioorg Med. chem. Lett.*, **10**: 513-515 (2000).
31. Terzioglu N., Gursoy A., *Eur. J. Med. Chem.* **38**: 781-786 (2003).
32. Singh V., Srivastava, V.K., Palit G., Shanker K., *Arzneim- Forsch. Drug.Res.* **42**: 993-996 (1992).
33. Savini L., Chiasseroni L., Travagli V., Pellerano C., Novellino E., Cosentino S., Pisano M.B., *Eur. J. Med. Chem.*, **39**: 113-122 (2004).
34. Kalsi R., Shrimali M., Bhalla T.N., Barthwal J.P., *Indian J.Pharm. Sci.*, **41**: 353-359 (2006).
35. Bernardino A., Gomes A., Charret K., Freitas A., Machado G., Cavalheiro M., Leon L., Amaral V., *Eur. J.Med .Chem.*, **41**: 80-87, (2006).
36. Silva A.G., Zapata-Suto G., Kummerle A.E., Fraga C.A.M., Barreiro E .J., Sudo R.T., *Bioorg Med. Chem.*, **13**: 3431-3437 (2005).